Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vidac Pharma HoldingSTU:T9G +1.94%21 EBITDA Margin % is 0.00% as of Jun. 2025. GuruFocus rates STU:T9G with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 943 Biotechnology companies, Vidac Pharma Holding ranks worse than 106044.43% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vidac Pharma Holding EBITDA Margin % Related Terms
Vidac Pharma Holding EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vidac Pharma Holding's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:T9G vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Vidac Pharma Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vidac Pharma Holding EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vidac Pharma Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vidac Pharma Holding (STU:T9G) has a EBITDA Margin % of 0.00% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vidac Pharma Holding and its competitors. According to the industry distribution chart, Vidac Pharma Holding ranks #999999 out of 943 companies in the Biotechnology industry.
Is Vidac Pharma Holding's EBITDA Margin % too high?
Vidac Pharma Holding's current EBITDA Margin % is 0.00%. Based on the distribution chart, Vidac Pharma Holding ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vidac Pharma Holding has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Vidac Pharma Holding's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vidac Pharma Holding ranks #999999 out of 943 companies for EBITDA Margin %. This places Vidac Pharma Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vidac Pharma Holding and its competitors. Vidac Pharma Holding's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vidac Pharma Holding stock overvalued right now?
Vidac Pharma Holding (STU:T9G) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Vidac Pharma Holding's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vidac Pharma Holding (STU:T9G), the current EBITDA Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company that focuses on discovering and developing medicines for oncologic and onco-dermatologic diseases. The company's research targets the modification of the tumor microenvironment to inhibit cancer cell growth by selectively affecting metabolic checkpoints in cancer cells without harming normal tissue. Its drug pipeline includes candidates such as VDA-1102 ointment, VDA-1102 IV, and VDA-1275, which are designed to treat conditions like Actinic Keratosis and Cutaneous T-cell Lymphoma. Vidac Pharma operates internationally with headquarters in London and aims to treat cancer through novel chemical entities.
21GF Score
Get the complete analysis for STU:T9G
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:T9G has been successfully added to your 
